Skip to main content
Terug
Watch Compare

GT Biopharma, Inc.

Datakwaliteit: 83%
GTBP
Nasdaq Manufacturing Chemicals
€ 0,37
▼ € 0,02 (-5,46%)
Marktkapitalisatie: 11,99 M
Prijs
€ 0,38
Marktkapitalisatie
11,99 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -12,91 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-967,55%
Onder sectorgemiddelde (-53,34%)
ROIC-251,08%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio3,27
Interest Coverage-97,81

Waardering

PE (TTM)
-0,42
Boven sectorgemiddelde (-1,47)
P/B Ratio4,00
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,4 -1,5
P/B 4,0 1,6
ROE % -967,6 -53,3
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

1 analist
Buy
Huidig
€ 0,37
+713.0%
Koersdoel
€ 3,00
€ 3,00
€ 3,00
€ 3,00
Vooruitzicht
Forward WPA -€ 0,26
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,26
-€ 0,26 – -€ 0,26
 0,0 1
FY2026 -€ 0,32
-€ 0,32 – -€ 0,32
 0,0 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,22 -€ 4,84 -2100,0%
Q32025 -€ 0,38 -€ 0,83 -118,4%
Q22025 -€ 0,68 -€ 0,55 +19,1%
Q12025 -€ 0,64 -€ 0,33 +48,4%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -28,35 M
ROE -967,55% ROA -495,48%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -12,91 M
ROIC -251,08% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,27
Interest Coverage -97,81 Asset Turnover N/A
Working Capital 3,00 M Tangible Book Value 3,00 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,42 Forward P/E N/A
P/B Ratio 4,00 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -107,70%
Market Cap 11,99 M Enterprise Value 9,46 M
Per Share
EPS (Diluted TTM) -6,68 Revenue / Share N/A
FCF / Share -0,41 OCF / Share -0,41
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 45,55%
SBC-Adj. FCF -13,30 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -28,35 M -13,16 M -7,60 M -20,88 M -58,01 M
EPS (Diluted) -6,68 -6,94 -5,64 — —
Gross Profit — — — — —
Operating Income -12,42 M -14,36 M -13,58 M -21,26 M -57,52 M
EBITDA — — — — —
R&D Expenses 3,47 M 5,80 M 6,47 M 8,81 M 9,59 M
SG&A Expenses 8,95 M 8,57 M 7,11 M 12,45 M 47,92 M
D&A — — — — —
Interest Expense 127.000,0 213.000,0 213.000,0 8.000,0 —
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8,11 M 4,23 M 14,11 M 16,74 M —
Total Liabilities 1,32 M — 6,63 M 5,00 M —
Shareholders' Equity 5,79 M -1,67 M 7,48 M 11,73 M 21,91 M
Total Debt — — — — —
Cash & Equivalents 6,81 M 3,95 M 1,08 M 5,67 M 32,00 M
Current Assets 8,11 M 4,23 M 14,06 M 16,56 M 32,17 M
Current Liabilities 2,32 M 5,90 M 6,63 M 4,94 M 10,26 M